News

News 19.06.2020 Schlieren, Switzerland – June 18, 2020   InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company will relocate its corporate headquarters and research and bioproduction laboratories to a larger facility in the Bio-Technopark Schlieren-Zürich life sciences building complex, positioned in the heart of the greater Zürich biotechnology hub....

News 08.06.2020 Zurich, Switzerland, June 4 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has successfully secured its series B financing round. Funds raised so far...

News 05.06.2020 Schlieren, Switzerland – 4 June 2020 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy. MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent...

News 26.05.2020 Zurich-Schlieren, May 26, 2020. Proteomedix, the Swiss cancer diagnostics company is pleased to announce the appointment of Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD, as Medical Advisor effective June 1, 2020. These accomplished executives bring a wealth of industry expertise to the...

News 19.05.2020 Zurich-Schlieren, Switzerland, May 19, 2020. Proteomedix, the Swiss cancer diagnostics company announces today the publication of the analytical performance results of Proclarix, Proteomedix lead product for improved prostate cancer diagnostics in the peer-reviewed journal PLOS ONE. The report published today highlights the analytical performance of the two CE-IVD assays that measure...